Personalized Approaches to HER2-Positive Breast Cancer Treatment

By clicking the continue button above, I certify I have read the CME/CNE/ABIM MOC statements below.

Release Date: March 15, 2022
Expiration Date: March 15, 2023

While In recent years, the treatment of HER2-positive metastatic breast cancer has improved significantly and become increasingly individualized. Several novel therapies have emerged that provide patients progressing on first-line therapy with improved treatment options that can be personalized to their individual treatment needs. Additionally, a novel subset of breast cancer comprising patients with low HER2 expression (IHC 1 or 2) has been identified that represents up to 40% of all metastatic breast cancer. Several novel agents are in development that specifically target this low HER2 expressing population.

This activity, Personalized Approaches to HER2-Positive Breast Cancer Treatment, will provide oncology clinicians with information on the most recent treatments for HER2-positive breast cancer, expert recommendations for treatment selection and sequencing, and how to identify and treat HER2-positive patients with low HER2 expression.

Welcome and Introduction
Personalized Treatment for Progressive HER2-Positive Breast Cancer
New Horizons in HER2-Positive Breast Cancer Care
Q&A Session and Activity Roundup

Reshma L. Mahtani, DO
 Chief of Breast Oncology
 Miami Cancer Institute
 Baptist Health South Florida
 Plantation, FL

Reshma L. Mahtani, DO is a medical oncologist practicing in South Florida. She serves as Chief of Breast Oncology at the Miami Cancer Institute, Baptist Health South Florida (a Memorial Sloane Kettering affiliate). Her practice is limited to breast cancer.

After completing her Master of Science degree in neuroscience at the University of Connecticut, Dr. Mahtani went on to the University of New England College of Osteopathic Medicine, where she received her medical degree. She completed internship at Greenwich Hospital, a Yale-affiliate, in Greenwich, Connecticut, and undertook residency training at St. Vincent’s Catholic Medical Center in New York, where she also completed her fellowship.

Prior to assuming her role at the Miami Cancer Institute, Dr.Mahtani was an Associate Professor of Medicine and Co-Leader of the Breast Cancer Program at Sylvester Comprehensive Cancer Center, University of Miami, where she oversaw the clinical trial program across the network. She is an active clinical researcher and her research focuses on novel therapies for the treatment of breast cancer. She has served on the ASCO Quality Oncology Practice Initiative (QOPI) Steering Committee and as a member of the editorial board of The Breast Journal and Practice Update (an online medical education platform for physicians). She has been Program Director for several officially licensed Best of ASCO programs and is the Director of the ASCO Highlights series. She has a passion for medical education and is Director of the Community Oncology Education Dinner Series, a program that hosts medical education events for oncologists and patients.

 Marissa Marti-Smith, APRN, AGNP-C, AOCNP
 Oncology Nurse Practitioner
 Baylor Sammons Cancer Center
 Dallas, TX

Marissa Marti-Smith, APRN, AGNP-C, AOCNP is an Adult-Geriatric Nurse Practitioner, currently working in Breast Oncology for the last 3 years with Dr. Joyce O'Shaughnessy in Dallas, TX. She has worked in Medical Oncology since 2009 as a Registered Nurse in various roles including inpatient and outpatient oncology nursing. After completing her MSN, she did teach full time at an ADN nursing program in Fort Worth, TX and has always been passionate about nursing education. Marissa is currently pursing her Doctor of Nursing Practice (DNP) with plans of completion in May 2023. She continues to be involved in participation of Breast Cancer research in her role as an APRN and helping make a difference in patients lives each and every day.

 Sara M. Tolaney, MD, MPH
 Chief, Division of Breast Oncology
 Associate Director, Susan F. Smith Center for Women’s Cancers
 Dana-Farber Cancer Institute
 Associate Professor of Medicine
 Harvard Medical School
 Cambridge, MA

Sara Tolaney, MD, MPH is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute and is internationally recognized for her research and education leadership in breast cancer.  She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School.

Dr. Tolaney received her undergraduate degree from Princeton University and her medical degree from UC San Francisco. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained her Masters in Public Health from Harvard School of Public Health. 

Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches. Her work has demonstrated that a relatively low risk regimen is beneficial in women with early-stage node-negative HER2-positive cancers, and this works has been incorporated into national and international guidelines.  She has developed several follow-up studies looking at novel approaches to early stage HER2-positive disease and has also played a significant role in development of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy in breast cancer. She currently chairs several registration studies in these areas and also leads many investigator-initiated trials. She is the author of over 150 peer-reviewed publications with manuscripts included in many prestigious journals such as the New England Journal, Lancet Oncology, Journal of Clinical Oncology, and JAMA Oncology.

The intended audience for this educational initiative is oncologists, pathologists, nurses, and other clinicians involved in the treatment of patients with breast cancer.

At the conclusion of this education, participants should be able to:
  • Assess the safety and efficacy of currently approved treatments for HER2-positive MBC
  • Develop patient-personalized treatment plans for patients with progressive HER2-positive MBC on the basis of patient and disease characteristics
  • Evaluate patients with breast cancer for HER2 expression level
  • Discuss emerging treatments in development for HER2 low expression MBC
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME/MOC credit or the evaluation, please email

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Rockpointe Corporation. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC)
Amedco LLC designates this activity for a maximum of 1 ANCC contact hour.
Click here to download the learner notification.

 Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To recieve CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME's ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, Personalized Approaches to HER2-Postive Breast Cancer has met the requirements as a Lifelong Learning CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

ABMS Lifelong Learning CME Activity
Family Medicine

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by PCME.

Faculty, Authors, and Content Developers
The faculty, authors and content developers reported the following relevant financial relationships with ineligible companies:

Reshma Mahtani, DO: Consulting Fee: Agendia, Amgen, AstraZeneca, Biotheranostics, Daiichi, Eisai, Genentech, Immunomedics, Lilly, Novartis, Merck, Pfizer, Puma, Sanofi, Seagen

Marissa Marti-Smith, APRN, AGNP-C, AOCNP: Consulting Fee: Biotheranostics, Novartis, Puma

Sara M. Tolaney, MD, MPH: Consulting Fee:
4D Pharma, AstraZeneca, Athenex, BeyondSpring Pharmaceuticals, Bristol Myers-Squibb, Certara, Chugai Pharmaceuticals, CytomX, Daiichi-Sankyo, Eisai, Eli Lilly, Ellipses Pharma, Genentech/Roche, Gilead/Immunonomedics, Kyowa Kirin Pharmaceuticals, Merck, Mersana Therapeutics, Nanostring, Nektar, Novartis, Odonate, OncXerna, OncoPep, OncoSec, Pfizer, Puma Biotechnology, Sanofi, Samsung Bioepsis, SeaGen, Zymeworks; Contracted Research: AstraZeneca, Bristol Myers-Squibb, Cyclacel, Eli Lilly, Eisai, Exelixis, Genentech/Roche, Gilead/Immunomedics, Merck, Nektar, Nanostring, Novartis, Pfizer, Sanofi, SeaGen
Planners and Managers
The planners and managers reported the following relevant financial relationships with ineligible companies: 

Chelsey Goins, PhD: Has no relevant relationships

Content Reviewers
The content reviewers reported the following relevant financial relationships with ineligible companies: 

Katie Propst, PhD: Has no relevant relationships

The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Please ensure the computer system you plan to use meets the following minimum requirements:
  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac & Windows): Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME/MOC activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.

Jointly provided by the Potomac Center for Medical Education and Rockpointe 


This program is supported by educational grants from AstraZeneca, Daiichi Sankyo, And Seagen.

Click here for the PCME Privacy Policy 


Facebook - RockPointe Twitter - RockPointe LinkedIn - RockPointe